Psoriatic Arthritis | Treatment Algorithms | Claims Data Analysis | US | 2018
MARKET OUTLOOK
Treatment for PsA typically begins with a cDMARD, but often progresses to a tsDMARD or bDMARD within two years. TNFi are the mainstay of treatment for recently treated patients, but newer therapies including two IL-17 inhibitors have a growing market share. Persistency and compliance are highest for Remicade, but Enbrel and Humira continue to capture the largest portion of the bDMARD market.
QUESTIONS ANSWERED
- How long do patients wait between a diagnosis and an initial prescription? How fast do newly diagnosed patients progress through lines of therapy?
- Where in the treatment algorithm will new therapies such as Taltz, Xeljanz, and Orencia fall?
- What changes have taken place in the treatment algorithm within the last three years? What therapies have a growing or shrinking market share?
- How compliant are PsA patients with their prescribed medication? What medications have the highest persistency?
Related Market Assessment Reports
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…
Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…
Report
Obesity / Overweight – Current Treatment – Treatment Algorithms: Claims Data Analysis – Obesity / Overweight (US)
As the prevalence of obesity rises, the demand for safe and effective treatments increases. Therapies mimicking GLP-1 and GIP peptides—hormones that regulate appetite and energy metabolism—have…
